Orthopedic implant manufacturers are operating in a fundamentally different evidence environment tha…
Despite decades of investment, the overwhelming majority of programs have failed in late-stage devel…
Organizations that continue to anchor development programs in broad diagnostic categories and legacy…
A substantial proportion of patients fail to achieve sustained remission. Treatment resistance remai…
Today, central nervous system (CNS) disorders are being redefined through molecular signatures, circ…
Alzheimer’s disease (AD) medicine development remains the most high-risk, high-investment domain in …
A significant proportion of patients remain treatment resistant. Among those who respond, relapse is…
For decades, psychiatry has approached major depressive disorder (MDD) as a disorder of neurochemist…
CNS disorders are now being reclassified by molecular signatures, circuit-level dysfunction, and dig…
Success in 2026 is driven by Translational Clarity: the ability to prove that biological changes tra…
Traditional pharmacotherapy primarily alters synaptic transmission. Neuromodulation platforms (such …
Converging evidence also points to impaired SN-mediated switching between the DMN and executive netw…
Advances in high-resolution functional MRI, multimodal imaging, and computational modeling over the …
At Salience Clinical, we operate at the intersection of systems neuroscience, clinical development s…
AAV-mediated delivery of enzymes, neurotransmitter-modulating proteins, or neurotrophic factors has …
Medical-device development is unlike typical software or manufacturing environments because products…
From Salience Clinical’s perspective, success over the next decade will depend on disciplined integr…
Healthcare systems face a growing economic crisis: more than 13 million patients suffer from chronic…
The next wave of musculoskeletal regenerative therapies won’t be decided by who has the most elegant…